Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials.
Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B. Yong K, et al. Among authors: cost p. Eur J Cancer. 2024 Nov 29;215:115157. doi: 10.1016/j.ejca.2024.115157. Online ahead of print. Eur J Cancer. 2024. PMID: 39673835
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting.
Alsdorf W, Diels J, Ghilotti F, Mendes J, Hernando T, Cost P, Schecter JM, Lendvai N, Patel N, Triguero A, Ursi M. Alsdorf W, et al. Among authors: cost p. J Comp Eff Res. 2024 Sep;13(9):e240080. doi: 10.57264/cer-2024-0080. Epub 2024 Aug 20. J Comp Eff Res. 2024. PMID: 39162049 Free PMC article. Clinical Trial.
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Burnett H, Cost P, Schecter JM, Lendvai N, Patel N, Ishida T, Er J, Harrison SJ, Lopez-Muñoz N. Bar N, et al. Among authors: cost p. Curr Med Res Opin. 2024 Sep;40(9):1597-1603. doi: 10.1080/03007995.2024.2391112. Epub 2024 Aug 22. Curr Med Res Opin. 2024. PMID: 39129504
Breastfeeding practices in Colorado businesses.
Dunn BF, Zavela KJ, Cline AD, Cost PA. Dunn BF, et al. Among authors: cost pa. J Hum Lact. 2004 May;20(2):170-7. doi: 10.1177/0890334404263739. J Hum Lact. 2004. PMID: 15117516